Direkt zum Inhalt
Toggle navigation
Live markets
Search
Search
Search
Search
My profile
My Subscriptions
Watchlists
Quote alerts
Create account
Sign in
DE
FR
EN
PT
NL
NB
DE
IT
Startseite
Company Press Releases
Company press releases
Abonnieren
Filter
Filter
Aktualisieren
Zurücksetzen
Icon After
Datum
Toggle Visibility
Alle
Heute
This week
This month
Custom date range
From
To
Topic
Toggle Visibility
Acquisition or disposal of the issuer’s own shares
Additional regulated information required to be disclosed under the laws of a Member State
Adjustment of interest rate
Alliances and agreements
Annual financial and audit Reports
Change in Capital
Changes in the rights attaching to the classes of shares or securities
Commercial operations
Commercial results
Corporate life
Dividend
Ex Date
General meeting / Board Meeting
Half yearly financial reports and audit reports/limited reviews
Home Member State
Income
Inside information
Joint venture
Journal / appointments
Legal
Major shareholding notifications
Mandatory notification of trade primary insiders
Meetings / events
Mergers, Acquiqitions, Transferts
New
New establishment
News contracts
Non-regulatory press releases
Other financial transaction
Other subject
Payments to governments
Polls / Surveys
Products and services
Prospectus / admission document
Rating
Sales
Share history
Share introduction and issues
Takeover bids
Total number of voting rights and capital
Trends / Analyses
Provider
Toggle Visibility
ActusNewsWire
BusinessWire
EQS Group
Euronext
GlobeNewswire
Les Echos
Marketwire
Modular Finance
Oslo Børs Newspoint
PR Newswire
Displaying 351 - 384 of 384 results
Released
Company
Title
Industry
Topic
23 Sep 2021
07:00 CEST
VALNEVA SE
Valneva Continues Expansion of Clinical Trials of its Inactivated COVID-19 Vaccine Candidate VLA2001
20103015 Pharmaceuticals
Products and services
14 Sep 2021
07:00 CEST
VALNEVA SE
Valneva finalise le recrutement de son essai de Phase 3 sur les personnes âgées pour son candidat vaccin inactivé contre la COVID-19
20103015 Pharmaceuticals
Products and services
14 Sep 2021
07:00 CEST
VALNEVA SE
Valneva Completes Recruitment of Elderly Participants in Phase 3 Trial of its Inactivated COVID-19 Vaccine
20103015 Pharmaceuticals
Products and services
13 Sep 2021
07:00 CEST
VALNEVA SE
Valneva reçoit un avis de résiliation par le gouvernement britannique de son contrat de fourniture de vaccins contre la COVID-19
20103015 Pharmaceuticals
Other subject
13 Sep 2021
07:00 CEST
VALNEVA SE
Valneva Receives Notice of Termination of COVID-19 Vaccine Supply Agreement by UK Government
20103015 Pharmaceuticals
Other subject
06 Sep 2021
18:00 CEST
VALNEVA SE
Déclaration d'actions et de droits de vote de la société Valneva SE - Août 2021
20103015 Pharmaceuticals
Legal
03 Sep 2021
07:00 CEST
VALNEVA SE
Valneva: U.S. DoD Exercises First Year Option on IXIARO® Supply Contract
20103015 Pharmaceuticals
Products and services
03 Sep 2021
07:00 CEST
VALNEVA SE
Valneva: le département américain de la Défense exerce la première option annuelle du contrat IXIARO®
20103015 Pharmaceuticals
Products and services
01 Sep 2021
18:15 CEST
VALNEVA SE
Valneva prendra part au 11ème symposium annuel des biotechs organisé par Goldman Sachs
20103015 Pharmaceuticals
Other subject
01 Sep 2021
18:15 CEST
VALNEVA SE
Valneva to Participate in Goldman Sachs Eleventh Annual Biotech Symposium
20103015 Pharmaceuticals
Other subject
23 Aug 2021
07:00 CEST
VALNEVA SE
Valneva commence la soumission progressive du dossier d’autorisation de mise sur le marché auprès de la MHRA pour son vaccin inactivé et adjuvanté contre la COVID-19
20103010 Biotechnology
Products and services
23 Aug 2021
07:00 CEST
VALNEVA SE
Valneva Commences Rolling Submission to MHRA for its Inactivated, Adjuvanted COVID-19 Vaccine
20103010 Biotechnology
Products and services
11 Aug 2021
17:45 CEST
VALNEVA SE
Valneva initie un essai de Phase 3 complémentaire pour son candidat vaccin contre la COVID-19
20103010 Biotechnology
Products and services
11 Aug 2021
17:45 CEST
VALNEVA SE
Valneva Initiates Further Phase 3 Clinical Trial for its COVID-19 Vaccine Candidate
20103010 Biotechnology
Products and services
10 Aug 2021
07:00 CEST
VALNEVA SE
Valneva Reports H1 2021 Financial Results and Provides Business Update
20103010 Biotechnology
New
10 Aug 2021
07:00 CEST
VALNEVA SE
Valneva publie ses résultats financiers du premier semestre 2021 et fait un point sur ses activités
20103010 Biotechnology
New
05 Aug 2021
07:00 CEST
VALNEVA SE
Valneva Announces Positive Phase 3 Pivotal Results for its Single-Shot Chikungunya Vaccine Candidate
20103010 Biotechnology
Products and services
05 Aug 2021
07:00 CEST
VALNEVA SE
Valneva annonce des résultats positifs pour l’étude pivot de Phase 3 de son candidat vaccin à injection unique contre le chikungunya
20103010 Biotechnology
Products and services
03 Aug 2021
18:35 CEST
VALNEVA SE
Déclaration d’actions et de droits de vote de la société Valneva SE – Juillet 2021
20103010 Biotechnology
Legal
29 Jul 2021
07:00 CEST
VALNEVA SE
Valneva nomme Peter Buhler au poste de Directeur Financier
20103010 Biotechnology
Journal / appointments
29 Jul 2021
07:00 CEST
VALNEVA SE
Valneva Appoints Peter Buhler as Chief Financial Officer
20103010 Biotechnology
Journal / appointments
19 Jul 2021
07:00 CEST
VALNEVA SE
Valneva et Pfizer finalisent le recrutement de l’essai de Phase 2 pour leur candidat vaccin contre la maladie de Lyme
20103010 Biotechnology
Products and services
19 Jul 2021
07:00 CEST
VALNEVA SE
Valneva and Pfizer Complete Recruitment for Phase 2 Trial of Lyme Disease Vaccine Candidate
20103010 Biotechnology
Products and services
07 Jul 2021
19:00 CEST
VALNEVA SE
VALNEVA: Déclaration d’actions et de droits de vote – Juin 2021
20103010 Biotechnology
Legal
07 Jul 2021
17:45 CEST
VALNEVA SE
Valneva reçoit le statut « Breakthrough Therapy » de la FDA pour son candidat vaccin à injection unique contre le chikungunya
20103010 Biotechnology
Products and services
07 Jul 2021
17:45 CEST
VALNEVA SE
Valneva Awarded FDA Breakthrough Designation for its Single-Shot Chikungunya Vaccine Candidate
20103010 Biotechnology
Products and services
06 Jul 2021
17:45 CEST
VALNEVA SE
Valneva renforce ses équipes dirigeantes et nomme Vincent Dequenne Vice-Président Senior en charge des Opérations Industrielles et Joshua Drumm Vice-Président des Relations Investisseurs
20103010 Biotechnology
Other subject
06 Jul 2021
17:45 CEST
VALNEVA SE
Valneva Strengthens Management Team; Appoints Vincent Dequenne as SVP Operations and Joshua Drumm as VP Investor Relations
20103010 Biotechnology
Other subject
05 Jul 2021
17:45 CEST
VALNEVA SE
Valneva organise un symposium scientifique sur ses candidats vaccins contre la COVID-19 et le chikungunya lors du 31ème Congrès européen de microbiologie clinique et des maladies infectieuses
20103010 Biotechnology
Alliances and agreements
05 Jul 2021
17:45 CEST
VALNEVA SE
Valneva to Host Symposium on COVID-19 and Chikungunya Vaccine Candidates at 31st European Congress of Clinical Microbiology & Infectious Diseases
20103010 Biotechnology
Alliances and agreements
01 Jul 2021
07:00 CEST
VALNEVA SE
Valneva Continues Ongoing Discussions with the European Commission for Inactivated COVID-19 Vaccine Candidate
20103010 Biotechnology
Other subject
01 Jul 2021
07:00 CEST
VALNEVA SE
Valneva poursuit ses discussions avec la Commission Européenne pour son candidat vaccin inactivé contre la COVID-19
20103010 Biotechnology
Other subject
23 Jun 2021
17:40 CEST
VALNEVA SE
Valneva Announces Successful Outcome of its AGM
20103010 Biotechnology
General meeting / Board Meeting
23 Jun 2021
17:40 CEST
VALNEVA SE
Valneva annonce l’approbation des résolutions présentées à son Assemblée Générale
20103010 Biotechnology
General meeting / Board Meeting
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Seitennummerierung
«
« First
‹
‹‹
6
7
8
Company press releases subscription
×
To subscribe to Press releases from this issuer, visit the Subscription to Company news section in
your account
section or
create an account
.
Home
Markets
Amsterdam
Cash Products
Stocks
AEX index Stocks
AEX ESG Stocks
Indices
Funds
Bonds
ETFs
Structured products
Derivative products
Index options
Index futures
Stock options
Dividend derivatives
Stock futures
Quote Vendor Codes
Company regulated news
Latest
Archive
Brussels
Cash products
Stocks
Euronext regulated
Euronext Growth
Euronext Access
Expert Market
BEL 20 Stocks
Indices
Bonds
ETFs
Structured Products
Derivative products
Index futures
Stock options
Stock futures
Dividend derivatives
Quote Vendor Codes
Company regulated news
Latest
Archive
Expert Market
Dublin
Stocks
Euronext regulated
Euronext Growth
ISEQ 20 Stocks
Indices
Funds
Bonds
Irish Government Bonds
DOL
Lisbon
Cash Products
Stocks
Euronext regulated
Euronext Access
PSI Stocks
Indices
Bonds
Derivative products
Index futures
Stock futures
Dividend derivatives
Quote Vendor Codes
Company regulated news
Latest
Archive
Milan
Cash Products
Stocks
Euronext Milan
Euronext Growth Milan
Euronext Star Milan
Euronext Global Equity Market
EuroTLX
Trading After Hours
MIB ESG Stocks
Bonds
MOT
Euronext Access Milan
EuroTLX
Structured Products
SeDeX
EuroTLX
ETFs
Funds
Derivative products
All derivatives
Index futures
Index options
Stock options
Stock futures
Dividend derivatives
Quote Vendor Codes
IPOs
Oslo
Cash Products
Stocks
Oslo Børs
Euronext Growth
Euronext Expand
Top performers
OBX stocks
OBX ESG Stocks
OSEBX stocks
OSEFX Stocks
Seafood Stocks
Shipping Stocks
Equity indices
Bonds
Oslo Børs
Nordic Alternative Bond Market
Bond indices
ETFs
Funds
Derivatives
Derivative products
Quote Vendor Codes
Company regulated news
Latest
Archive
Financial calendars
Primary insiders
Paris
Cash Products
Stocks
Euronext regulated
Euronext Growth
Euronext Access
CAC 40 Stocks
CAC 40 ESG Stocks
Indices
Bonds
ETFs
Structured products
Derivative products
Index futures
Index options
Stock options
Stock futures
Dividend derivatives
Quote Vendor Codes
Company regulated news
Latest
Archive
Aktien
All Markets directories
All Markets
Euronext regulated
Euronext Growth
Euronext Access
Euronext Expand
Euronext Global Equity Market
EuroTLX
Trading After Hours
Company regulated news
Latest
Archive
IPOs
All IPOs
Listing sponsors
Euronext Tech Leaders
Family business
Indices
Directory
ESG indices
Indices documents
Indices news
Index consultations
Contact Euronext indices
ETFs
Directory
ESG ETFs
Funds
Directory
ESG Funds
Oslo Mutual Funds
Fixed Income
ESG Bonds
1.5° Bonds
All Markets directories
All Markets
Amsterdam
Brussels
Dublin
Lisbon
Oslo
Milan
Paris
Structured Products
Directory / search
Bid-Only trading status
Trading Turbos in the Netherlands
Equity Derivatives
Index Futures
Index Options
Stock Options
Stock Futures
Dividend Derivatives
ETF Options
Contracts specifications
Tick Sizes
Wholesale Trading
Quote vendor codes
Rohstoffe
Kurse
Kurse überblick
Weizen Future
Rapssaat Future
Mais Future
European Durum Wheat Futures
Weizen Optionen
Rapssaat Optionen
Mais Optionen
Handelskalender
Lieferung
Wholesale Trading
Commitments of Traders (CoT) report
Spezifikationen
Vendor Codes
Knowledge Centre
Bid & Ask
Options Investing E-learning
Contract Specifications
Position Management
Intrinsic Value
Premium & Valuation
Moneyness
Positions
Euronext News
Resources
Statistics & reports
Quality of execution
Trading hours & Holidays
Contract specifications
Quote vendor codes
Key Information Document
Class level
Product group level
Notices / Corporate actions
Cash Notices / Corporate actions
Derivatives corporate actions
All Corporate Actions
Latest
Unusual Contract Sizes, Dividends
Corporate Action Services
Corporate Action Policies
Derivatives notices
Market events
Suspended instruments
Stressed Market Conditions
Breach of Double Cap limits
Exceptional Market Conditions
Miscellaneous short messages
Market status
Members list
Issuers compliance
Where to find